

### Global Source Ventures, LLC Introduction

Antonius Schuh | Managing Partner Stephen Zaniboni | Managing Partner



## **Introduction to Global Source Ventures**


GSV provides seed capital to emerging companies with emphasis in the pharmaceutical and biotechnology industries



- Partnership of successful biotechnology executives
- Building a portfolio of technology companies through direct investments
- Proven success in investing, financing & operating healthcare and technology companies
- International perspective and global network



### **Our Investment Criteria**





# **Adding Value to Investments**



Access to international financial markets for healthcare, life sciences companies



Direct investments and advisory services to achieve value creation for strategically timed liquidity events



Trusted and effective strategic partners, incl. investors, bankers, legal advisors, accountants, consultants



Understanding of organizational and operational requirements for development stage companies



# **Our Managing Partner Team**

### Antonius Schuh, PhD

#### **Investment Experience**

- Raised over \$350M in venture capital, debt financing and IPO proceeds
- Completed 4 M&A transactions totaling over \$300M

#### **Chief Executive Officer Experience**

 SelectION, Cardiff Oncology (formerly Trovagene), Sorrento Therapeutics, AviaraDx, Arcturus Bioscience, Sequenom

#### **Executive Experience**

 Business Development Head at Helm AG Germany, Fisons Pharmaceuticals PLC, UK

### Stephen Zaniboni, CPA, MBA

#### **Investment Experience**

- Raised over \$600M in venture capital, debt financing and IPO proceeds
- Completed 4 M&A transactions totaling over \$300M
- · Section 16 officer and public company experience

#### **Financial Experience**

- CFO of SelectION, Soluventis Nanotherapeutics, Cardiff Oncology (formerly Trovagene), AviaraDx, Arcturus Bioscience, Sequenom, Awarepoint, XIFN
- Implemented SOX 404 standards and corporate governance in multiple organizations
- Experienced human resources, public relations, investor relations executive

# **Our Team (cont.)**

### Edvin N. Munk

#### VP, Europe

<u>Focus</u>: identifying and developing promising investment opportunities in Europe for innovative therapeutics and diagnostics

#### **Professional Experience**

- 20+ years experience in the life sciences and diagnostics industry
- Held multiple global management positions at Sequenom, Inc. and Agena, Inc.
- Currently serves as President of Soluventis Nanotherapeutics

### Michelle Zaniboni, CFA

#### VP, Investment Management

<u>Focus</u>: operations of portfolio companies; modeling, IR & fund raising, accounting, treasury, financial planning and executional support

#### **Professional Experience**

- Currently serves as VP of Finance of Soluventis Nanotherapeutics and consults for SelectION
- 4+ years experience as Research Associate at GMP Securities covering 40+ debt securities across several sectors

### **Elizabeth Anderson, CPA**

#### VP, Financial Operations

<u>Focus</u>: financial operations of portfolio companies including, accounting, treasury and budgeting, tax compliance and statements

#### **Professional Experience**

- 25 +years of finance and operations experience in life science industry
- Began career at Ernst & Young, with several years in Milan, Italy office
- Senior positions at Cardiff Oncology (formerly Trovagene), Neothetics, GenVault, Kalypsys and Sequenom



## Value Add

# Investors and advisors to companies preparing for financing and liquidity events

- Direct investment and introduction to investor network
- Support for corporate transactions and partnerships
- Advise on compliance with U.S. business, accounting, regulatory and legal standards
- Assist in development of U.S. investment banking relationships
- Aid in preparation for liquidity events such as IPO or M&A transactions



### **Select Holdings**



# **Recent Portfolio Company Events**

### 2020

VelosBio completes \$137M Series B

**Oncternal** receives Orphan Drug Designation of cirmtuzumab

Oncternal completes \$5M direct offering Avalyn Pharma completes \$35.5M Series B Retrotope receives Orphan Drug Designation for RT001

### 2019

Annikki completes Series B Annikki forms joint venture Treemera Immusoft completes \$20M Series B Oncternal (NASDAQ: ONCT) reverse merges with GTx, Inc. Retrosense achieves clinical development milestone Retrotope completes \$20M Series C Retrotope completes enrollment of Phase 2/3 trial in patients with INAD selectION raises \$4.1M Series A Soluventis Nanotherapeutics raises \$0.4M in additional seed funding

### 2018

Immusoft receives Orphan Drug and Pediatric Pediatric Disease Designation
selectION completes \$0.5M bridge round
Soluventis Nanotherapeutics, Inc. formed and raises \$0.5M in seed funding
VelosBio completes \$58M Series A
Zavante acquired by Nabriva (NASDAQ: NBRV)



### Mass spectrometry based DNA analysis technology: From Germany to San Diego, CA, U.S.

- German genomics start-up founded in 1994
- Organizational relocation in San Diego, U.S. in 1998
- Secured \$60M in private financing
- Non-invasive prenatal test (NIPT) for the detection of trisomies first introduced by Sequenom is today widely used clinical standard of care
- Grew revenue to ~\$30M annually
- NASDAQ IPO (Feb. 2000) raising \$160M at ~ \$700M post-money valuation
- Average return for private investors: approximately 9x





# Molecular Dx technology with attractive stand alone value proposition extracted from Arcturus Inc. and recapitalized

- Remaining diagnostic IP post asset sale of Arcturus instrument business
- AviaraDx was founded in 2006, Raised \$8M Series A investment in 2007
- Established CLIA lab; developed and launched CancerTYPE ID<sup>®</sup> and Breast Cancer Index<sup>®</sup> (BCI) tests
  - BCI is included in ASCO & EGTM guidelines, and is a widely used clinical standard of care
  - CancerTYPE ID® has achieved attractive reimbursement coverage by CMS, is widely used, and with treatment, was shown to improve patient outcomes by 9 months
- Managed a dual track strategy: competitive M&A process and Series B funding
- Sold company to BioMerieux in 2008 for \$60M. Return for Series A investors: 8x





# Biopharmaceutical company focused on discovery and development of fully human therapeutic antibodies and immunotherapies

- Co-founded company in 2006 ("San Diego Antibody Corp.") based on pending patent application for the construction of extremely large libraries of fully human monoclonal antibodies (mAbs) U.S. patent issued in late 2008
- Raised initial working capital through reverse merger into a public shell in early 2009
- NASDAQ listing in the fall of 2013
- Current pipeline includes proprietary PD-L1 and anti-PD-1 checkpoint inhibitors
- Chimeric Antigen Receptor-T Cell (CAR-T) and Chimeric Antigen Receptor Natural Killer (NK) Cells (CAR. NK<sup>™</sup>) programs underway
- Successful exit for GSV concluded in 2015
- Return for public shell investors at peak share price (\$26.80/share; 7/23/2015): 27x





### Developing a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor for cancer treatment

Presented company with business plan focused on precision cancer monitoring in Q3 2011

- Engaged for turn around including strategy, fund raising and organizational development Q4 2011
- Led NASDAQ listing; raised ca. \$115M in equity and debt over 4 years
- Built a fully functional organization including R&D and Commercial teams
- Led organization to clinical validation and product launch
- Legal dispute with legacy board resulted in highly favorable settlement for GSV principals
- 3x return for original investors as of March 2016



### Developing a novel gene therapy approach to vision restoration

- Company formed to help restore vision to patients with retinitis pigmentosa and advanced dry age-related macular degeneration
- In mid 2014, GSV participated in a Series A financing round to fund Phase I/II clinical trials
- Received Orphan drug status for its lead product RST-001 for retinitis pigmentosa
- Phase I/II clinical trials commenced in March 2016
- Successful exit via sale to Allergan plc (NYSE: AGN) in September 2016
- Upfront payment + milestones received yield 5.3x return on our initial investment
- Return significantly increases if potential regulatory and commercialization milestone payments related to RST-001 are reached



# Thank you. For more information please contact:

Global Source Ventures | 655 India St., Suite 204 | San Diego | CA 92101 | USA | Tel: +1 858 967-8014

